News from novartis pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 26, 2016, 09:47 ET

Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis

 Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for two new indications -...

Jan 25, 2016, 16:30 ET
Tim, patient, is wearing the BRAF+ marking

Novartis teams up with Pro Football Hall of Famer Troy Aikman on advanced melanoma educational and community support program

 Pro Football Legend, Hall of Famer and former melanoma patient Troy Aikman is teaming up with Novartis and the advocacy community to educate...

Dec 23, 2015, 17:04 ET

Novartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis

 Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing...

Dec 07, 2015, 15:03 ET

Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL

The latest findings from an ongoing Phase II study of CTL019, an investigational chimeric antigen receptor T cell (CART) therapy, further support...

Dec 06, 2015, 11:15 ET

Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations

 Novartis today announced positive results from the global Phase III RATIFY (CALGB 10603) clinical trial. In the study, adult patients under 60...

Dec 06, 2015, 07:46 ET

Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma

 Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell (CART)...

Nov 30, 2015, 07:15 ET

Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research

 Novartis will demonstrate the strength of its research program and portfolio at the 57th American Society of Hematology (ASH) Annual Meeting....

Nov 20, 2015, 17:14 ET

Novartis receives FDA regular approval for Tafinlar® + Mekinist® to treat aggressive form of melanoma based on long-term survival data

Novartis today announced that the US Food and Drug Administration (FDA) has granted regular approval for the combination of Tafinlar®...

Nov 10, 2015, 17:30 ET
Why rehospitalizations for heart failure matter

Novartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows

 Novartis announced today data from a new analysis demonstrating that fewer heart failure patients with reduced ejection fraction (HFrEF)...

Nov 07, 2015, 19:37 ET

Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data

Novartis announced two-year data for Cosentyx® (secukinumab) from an observational sub-analysis of a pivotal Phase III trial showing no...

Nov 07, 2015, 19:37 ET

Up to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data

 Novartis announced two-year data for Cosentyx® (secukinumab) from an observational sub-analysis of a pivotal Phase III trial showing up...

Oct 29, 2015, 16:50 ET

FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease

 Novartis announced today that the US Food and Drug Administration (FDA) has approved the dual combination bronchodilator Utibron™...

Sep 30, 2015, 17:04 ET

Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis

 Novartis announced today that results from the pivotal Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published...

Sep 27, 2015, 18:02 ET

Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®

 Novartis today announced updated data from the Phase III COMBI-v study showing a significant overall survival benefit for patients with BRAF...

Sep 24, 2015, 12:30 ET
Access to Noncommunicable Disease Treatment

Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries

Novartis today announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income...

Aug 24, 2015, 19:07 ET

FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia

Novartis announced today that the US Food and Drug Administration (FDA) has approved an expanded use for Promacta® (eltrombopag) to include...

Jul 07, 2015, 16:50 ET

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)

Novartis announced today that the US Food and Drug Administration (FDA) has approved Entresto™ (sacubitril/valsartan) tablets, previously...

Jun 11, 2015, 18:31 ET

Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder

Novartis announced today that the US Food and Drug Administration (FDA) has approved Promacta® (eltrombopag) for the treatment of children six...

Jun 01, 2015, 16:07 ET

Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma

 Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell...

Jun 01, 2015, 09:00 ET

Novartis presents new data at ASCO for Zykadia™ and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs

 Novartis today announced new data from two Phase II studies of Zykadia™ (ceritinib), as well as one Phase II study of Tafinlar®...